Overview
- The World Health Organization issued its first guideline conditionally recommending GLP-1 therapy for adult obesity alongside behavioral care, projecting access to fewer than 10% of eligible people by 2030 and urging pricing and licensing strategies to broaden supply.
- Australia’s TGA updated product warnings to flag possible mood changes and suicidal ideation with GLP-1s and advised non‑oral or added barrier contraception for four weeks after starting or increasing tirzepatide due to a potential interaction.
- The Delhi High Court refused Novo Nordisk’s bid for an interim injunction and allowed Dr. Reddy’s to manufacture and export semaglutide, citing a credible patent challenge and characterizing Novo’s filings as double patenting.
- Novo Nordisk is preparing an India push as Reuters reports Ozempic could launch locally within weeks, a timeline the company has not confirmed.
- Novo’s oral semaglutide did not slow cognitive decline in Phase 3 Alzheimer’s trials despite modest biomarker shifts, and WADA says GLP-1s remain under monitoring for potential sports misuse with no current ban.